P-683 Pegfilgrastim supports dose-dense carboplatin/vinorelbine in the treatment of thoracic malignancies

Riedel, Richard F.; Garst, Jennifer; Dunphy, Frank; Herndon, James E.; Blackwell, Susan; Campagna, Lara; Bjurstrom, Antoinette; Young, K.; Yowell, Sally; Crawford, Jeffrey

doi:10.1016/s0169-5002(03)92650-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two other studies have evaluated the utility of pegfi lgrastim administered on day 9 during days 1 and 8 chemotherapy regimens -carboplatin+vinorelbine [17] and docetaxel+gemcitabine [18] in patients with lung cancer. As in this study, there were few cases of severe grade 4 neutropenia or FN.…”

Section: Discussionmentioning

confidence: 99%

Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen

Mattioli¹,

Gridelli

Castellanos

et al. 2009

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen

Mattioli¹,

Gridelli

Castellanos

et al. 2009

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

“…Of concern is the possibility of stem-cell damage because of the long half-life of the agent, which may extend its activity into subsequent cycles of chemotherapy. The preliminary results of trials of dose-dense chemotherapy with pegfilgrastim in patients with many different tumor types suggest, however, that this agent provides safe and effective neutrophil support [28][29][30] and makes adherence to the planned dose possible. 28,29 Other potential hematologic toxicities that can limit dose-intense therapy are anemia, which is treated with recombinant human erythropoietin or red blood cell transfusions, and thrombocytopenia, which is treated with recombinant interleukin-11 or platelet transfusions.…”

Section: Feasibility Of Dose-intense Regimensmentioning

confidence: 99%

Chemotherapy Dose Density in Early‐Stage Breast Cancer and Non‐Hodgkin's Lymphoma

Goldspiel

2004

Pharmacotherapy

View full text Add to dashboard Cite

Delivering standard-dose chemotherapy on schedule is important for survival in early-stage breast cancer and non-Hodgkin's lymphoma. Trials of dose-escalated regimens, in which higher-than-standard doses of chemotherapy are used, have produced equivocal results. In contrast, dose-dense regimens, in which standard doses are given with shorter (usually 14-day) intervals between cycles, have been more efficacious than standard 21-day regimens in trials in both early-stage breast cancer and non-Hodgkin's lymphoma. Furthermore, a shorter course of chemotherapy is likely to cause less disruption in patients' lives. Despite the evidence of the importance of maintaining chemotherapy dose intensity (the amount of drug administered/unit of time), undertreatment of patients with early-stage breast cancer and non-Hodgkin's lymphoma is common. Neutropenia is the primary dose-limiting toxicity of many chemotherapy regimens, and it is frequently managed by dose reductions and delays that decrease dose intensity. Colony-stimulating factors reduce the prevalence and severity of neutropenia and its complications, and their proactive use can improve adherence to the planned schedule of both standard-dose and dose-dense chemotherapy The promising results with dose-dense chemotherapy in early-stage breast cancer and non-Hodgkin's lymphoma indicate that it should be tested in patients with other chemosensitive tumors.

show abstract

P-683 Pegfilgrastim supports dose-dense carboplatin/vinorelbine in the treatment of thoracic malignancies

Cited by 2 publications

References 0 publications

Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen

Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen

Chemotherapy Dose Density in Early‐Stage Breast Cancer and Non‐Hodgkin's Lymphoma

Contact Info

Product

Resources

About